FDA provides accelerated approval of Talvey for multiple myeloma
The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
Aug 16, 2023
0
1
The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
Aug 16, 2023
0
1
A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.
Jan 31, 2024
0
15
New research questions the effectiveness of the U.S. Food and Drug Administration's accelerated drug approval program after finding that many cancer drugs remain unproven five years later.
Apr 8, 2024
0
2
Over the past decade, regulatory agencies such as the Federal Drug Administration (FDA) in the United States and the and the European Medicines Agency (EMA) in the European Union have put programs in place to get new drugs ...
Mar 13, 2024
0
0